InsidersTradesSigma
Total declarations
Company
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by OLER ABRAHAM N., Vice-Président et Conseiller Général. Officer active across 1 companies, notably Onconova Therapeutics, Inc.. Cumulatively, 14 disclosures have been logged. Total volume traded: €45k. The latest transaction was filed on 28 January 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
€2,2471,500 shares@ €1.49826.3% of flow
Common Stock
SEC:0001179110-22-000652·
Ideal exit: 25 Oct 2022 (T+270)
€2,2471,500 shares@ €1.49823.2% of flow
Common Stock
SEC:0001179110-22-000652:0·
Ideal exit: 25 Oct 2022 (T+270)
€2,6781,500 shares@ €1.78547.5% of flow
Common Stock
SEC:0001179110-22-000564·
Ideal exit: 18 Oct 2022 (T+270)
€2,6781,500 shares@ €1.78543.8% of flow
Common Stock
SEC:0001179110-22-000564:0·
Ideal exit: 18 Oct 2022 (T+270)
€2,8801,500 shares@ €1.92028.1% of flow
Common Stock
SEC:0001415889-22-000588·
Ideal exit: 11 Oct 2022 (T+270)
€2,8801,500 shares@ €1.92024.0% of flow
Common Stock
SEC:0001415889-22-000588:0·
Ideal exit: 11 Oct 2022 (T+270)
€3,1731,500 shares@ €2.11568.9% of flow
Common Stock
SEC:0001179110-22-000350·
Ideal exit: 4 Oct 2022 (T+270)
€3,1731,500 shares@ €2.11564.5% of flow
Common Stock
SEC:0001179110-22-000350:0·
Ideal exit: 4 Oct 2022 (T+270)
€2,7801,000 shares@ €2.77967.8% of flow
Common stock
SEC:0001415889-21-005425·
Ideal exit: 16 Aug 2022 (T+270)
€2,7801,000 shares@ €2.77963.9% of flow
Common stock
SEC:0001415889-21-005425:0·
Ideal exit: 16 Aug 2022 (T+270)
€13,2495,000 shares@ €2.649937.3% of flow
Common Stock
SEC:0001179110-21-010259·
€13,2495,000 shares@ €2.649918.6% of flow
Common Stock
SEC:0001179110-21-010259:0·
€8,5572,381 shares@ €3.593924.1% of flow
Common Stock
SEC:0001179110-21-008982·
Ideal exit: 25 Jun 2022 (T+270)
€8,5572,381 shares@ €3.593912.0% of flow
Common Stock
SEC:0001179110-21-008982:0·
Ideal exit: 25 Jun 2022 (T+270)
14 of 14 declarations
About OLER ABRAHAM N.
Abraham N. Oler serves as Senior Vice President of Corporate Development and General Counsel at Onconova Therapeutics, Inc. In this role, he oversees the legal and strategic aspects of the company, ensuring that operations comply with applicable regulations. Abraham brings valuable expertise in business law and transactions, contributing to Onconova's mission in developing innovative treatments.
